Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

CRIA News

Spring 1998

Twice a Day Crixivan™ Study

Both common sense and research studies dictate that the fewer times that pills have to be taken per day, the more likely people are to take them consistently. With this in mind, several manufacturers of protease inhibitors which are usually taken three times a day have begun to study their use twice a day. Preliminary data from studies conducted by Merck and Agouron in persons who are protease inhibitor naïve suggest that it may be possible to take Crixivan™ (indinavir) and Viracept™ (nelfinavir) twice a day. The duration of follow-up of these relatively small studies is limited to date, so it is not known definitively whether the twice a day dosing is as safe and effective as the three times a day dosing. None of the studies reported thus far have taken people who are already on the usual dose and switched them to twice a day dosing.

CRIA is participating in a multicenter study sponsored by Merck which is designed to address the question of whether persons taking the usual dose of Crixivan™ can safely be changed to twice a day dosing (see Trials). In this study, eligible persons who have been taking Crixivan™ plus two nucleoside analog drugs for at least six months and have viral loads less than 400 will be randomly assigned to continue the usual dose of 800 mg every 8 hours or to switch to 1200 mg every 12 hours. For more information, call Dr. Douglas Mendez at 212-924-3934.


New Community Advisory Board

CRIA is in the process of establishing a volunteer Community Advisory Board (CAB) to provide oversight of our Treatment Education Program. The CAB will review and evaluate all service components of this critical program on a regular basis. Its purpose will be to ensure that treatment education is provided in a culturally and linguistically appropriate format to a broad and fully inclusive cross section of people living with AIDS in New York City.

CRIA is accepting nominations for the CAB membership. If you know a PLWA who is interested in volunteering to serve on our CAB, please fax or mail a letter of recommendation to CRIA. No phone calls please.

Advertisement

CRIA's Women's Treatment Education Services

CRIA is proud to announce an initiative to provide specialized treatment education sessions to underserved women living with HIV/AIDS in New York City. This initiative has been made possible by the generous support of the Liz Claiborne Foundation. Contact CRIA's Treatment Education Department at 212- 924-3934 for information on how to access this service.


Back to CRIA Update Spring 98 Contents Page



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by AIDS Community Research Initiative of America. It is a part of the publication CRIA Update. Visit ACRIA's website to find out more about their activities, publications and services.
 

Tools
 

Advertisement